Next Article in Journal / Special Issue
Gut Microbiota and Iron: The Crucial Actors in Health and Disease
Previous Article in Journal / Special Issue
How Eliminating Malaria May Also Prevent Iron Deficiency in African Children
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessReview
Pharmaceuticals 2018, 11(4), 97;

Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation

Department of Internal Medicine, University Hospital Virgen de la Victoria. Campus de Teatinos, 2010 Málaga, Spain
Scientific Department, Alesco S.r.l. Via delle Lenze, 216/B, 56122 Pisa, Italy
Scientific Department, Pharmanutra S.p.A. Via delle Lenze, 216/B, 56122 Pisa, Italy
Perioperative Transfusion Medicine, Department of Surgical Specialties, Biochemistry and Immunology, School of Medicine, Campus de Teatinos, 29071 Málaga, Spain
Author to whom correspondence should be addressed.
Received: 30 August 2018 / Revised: 28 September 2018 / Accepted: 2 October 2018 / Published: 4 October 2018
(This article belongs to the Special Issue Iron as Therapeutic Targets in Human Diseases)
Full-Text   |   PDF [2387 KB, uploaded 15 October 2018]   |  


Iron deficiency (ID) is usually treated with oral iron salts, but up to 50% of patients complain of gastrointestinal side effects, leading to reduced compliance with treatment. Intravenous (IV) iron formulations are increasingly safe, but there is still a risk of infusion, hypersensitivity reactions and the need for venous access and infusion monitoring. Sucrosomial® Iron (SI) is an innovative oral iron formulation in which ferric pyrophosphate is protected by a phospholipid bilayer plus a sucrester matrix (sucrosome), which is absorbed through para-cellular and trans-cellular routes (M cells). This confers SI’s unique structural, physicochemical and pharmacokinetic characteristics, together with its high iron bioavailability and excellent gastrointestinal tolerance. The analysis of the available evidence supports oral SI iron as a valid option for ID treatment, which is more efficacious and tolerable than oral iron salts. SI has also demonstrated a similar effectiveness, with lower risks, in patients usually receiving IV iron (e.g., chronic kidney disease, cancer, bariatric surgery). Thus, oral SI emerges as a valuable first option for treating ID, especially for subjects with intolerance to iron salts or those for whom iron salts are inefficacious. Moreover, SI should also be considered as an alternative to IV iron for initial and/or maintenance treatment in different patient populations. View Full-Text
Keywords: Anemia; iron deficiency; oral iron salts; intravenous iron; Sucrosomial® iron; M cells; bioavailability; tolerability; efficacy Anemia; iron deficiency; oral iron salts; intravenous iron; Sucrosomial® iron; M cells; bioavailability; tolerability; efficacy

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Gómez-Ramírez, S.; Brilli, E.; Tarantino, G.; Muñoz, M. Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation. Pharmaceuticals 2018, 11, 97.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top